 Melanoma
"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Descriptor ID |
D008545
|
| MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
| Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 3 | 0 | 3 | | 1991 | 3 | 0 | 3 | | 1992 | 5 | 0 | 5 | | 1993 | 3 | 1 | 4 | | 1994 | 5 | 0 | 5 | | 1995 | 3 | 1 | 4 | | 1996 | 3 | 1 | 4 | | 1997 | 6 | 0 | 6 | | 1998 | 5 | 0 | 5 | | 1999 | 5 | 0 | 5 | | 2000 | 7 | 2 | 9 | | 2001 | 5 | 1 | 6 | | 2002 | 6 | 3 | 9 | | 2003 | 5 | 2 | 7 | | 2004 | 5 | 1 | 6 | | 2005 | 15 | 1 | 16 | | 2006 | 13 | 3 | 16 | | 2007 | 12 | 2 | 14 | | 2008 | 16 | 2 | 18 | | 2009 | 18 | 1 | 19 | | 2010 | 9 | 3 | 12 | | 2011 | 16 | 1 | 17 | | 2012 | 25 | 3 | 28 | | 2013 | 22 | 4 | 26 | | 2014 | 15 | 4 | 19 | | 2015 | 9 | 4 | 13 | | 2016 | 17 | 1 | 18 | | 2017 | 31 | 1 | 32 | | 2018 | 23 | 2 | 25 | | 2019 | 20 | 2 | 22 | | 2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, Broit N, Amato CM, Van Gulick R, Kazakoff SH, Patch AM, Koufariotis LT, Lakis V, Leonard C, Wood S, Holmes O, Xu Q, Lewis K, Medina T, Gonzalez R, Saw RPM, Spillane AJ, Stretch JR, Rawson RV, Ferguson PM, Dodds TJ, Thompson JF, Long GV, Levesque MP, Robinson WA, Pearson JV, Mann GJ, Scolyer RA, Waddell N, Hayward NK. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 10 16; 11(1):5259.
-
Iwanaga R, Truong BT, Hsu JY, Lambert KA, Vyas R, Orlicky D, Shellman YG, Tan AC, Ceol C, Artinger KB. Loss of prdm1a accelerates melanoma onset and progression. Mol Carcinog. 2020 09; 59(9):1052-1063.
-
Shellman MH, Shellman YG. Human against Machine? Machine Learning Identifies MicroRNA Ratios as Biomarkers for Melanoma. J Invest Dermatol. 2020 01; 140(1):18-20.
-
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133.
-
Gonzalez CD, Pona A, Walkosz BJ, Dellavalle RP. Hispanic Tattoo Artists Could Provide Skin Cancer Prevention via Aftercare Instructions and Social Media J Drugs Dermatol. 2019 Dec 01; 18(12):1237-1243.
-
Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
-
Carmichael H, King BBT, Friedman C, Torphy RJ, Medina T, Gleisner A, McCarter MD, Kwak JJ, Kounalakis N. Frequency and implications of occipital and posterior auricular sentinel lymph nodes in scalp melanoma. J Surg Oncol. 2019 Dec; 120(8):1470-1475.
-
Friedman C, Lyon M, Torphy RJ, Thieu D, Hosokawa P, Gonzalez R, Lewis KD, Medina TM, Rioth MJ, Robinson WA, Kounalakis N, McCarter MD, Gleisner AL. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. J Surg Oncol. 2019 Dec; 120(7):1276-1283.
-
Yeh I, Jorgenson E, Shen L, Xu M, North JP, Shain AH, Reuss D, Wu H, Robinson WA, Olshen A, von Deimling A, Kwok PY, Bastian BC, Asgari MM. Targeted Genomic Profiling of Acral Melanoma. J Natl Cancer Inst. 2019 10 01; 111(10):1068-1077.
-
Mackin AG, Pecen PE, Dinsmore AL, Patnaik JL, Gonzalez R, Robinson WA, Palestine AG. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|